Air quality advisories issued in 5 provinces, 1 territory
Air quality advisories are in effect across Western Canada as smoky conditions plague some areas, according to the latest forecasts. Here's where.
An experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening -- but the anxiously awaited new data leaves unclear how much difference that might make in people's lives.
Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better treatments of the incurable disease.
Late Tuesday, the companies provided full results of the study of nearly 1,800 people in early stages of the mind-robbing disease. The data was presented at an Alzheimer's meeting in San Francisco and published in The New England Journal of Medicine.
Lecanemab delayed patients' worsening by about five months over the course of the 18-month study, Eisai's Dr. Michael Irizarry told The Associated Press. Also, lecanemab recipients were 31 per cent less likely to advance to the next stage of the disease during the study.
"That translates to more time in earlier stages" when people function better, Irizarry said.
Every two weeks, study participants received intravenous lecanemab or a dummy infusion. Researchers tracked them using an 18-point scale that measures cognitive and functional ability.
The study's key finding: Those given lecanemab declined more slowly, a difference of not quite half a point on that scale over the 18 months, concluded the research team led by Dr. Christopher van Dyck at Yale University.
Doctors are divided over how much difference that may make for patients and families -- especially as the drug carries some worrying potential safety risks including brain swelling.
"It is unlikely that the small difference reported in this trial will be noticeable by individual patients," said Dr. Madhav Thambisetty of the National Institute on Aging, who noted he wasn't speaking for the government agency.
He said many researchers believe a meaningful improvement would require at least a difference of a full point on that 18-point scale.
But Dr. Ron Petersen, an Alzheimer's expert at the Mayo Clinic, said the drug's effect was "a modest one but I think it's clinically meaningful" -- because even a few months' delay in progression could give someone a little more time when they're functioning independently.
The trial is important because it shows a drug that attacks a sticky protein called amyloid -- considered one of several culprits behind Alzheimer's -- can delay disease progression, said Maria Carrillo, chief science officer for the Alzheimer's Association.
"We all understand that this is not a cure and we're all trying to really grasp what it means to slow Alzheimer's, because this is a first," Carrillo said.
But any delay in cognitive decline early on could be meaningful for "how much time we have with our loved ones in a stage of disease where we can still enjoy family and outings, vacations, bucket lists," she said.
Amyloid-targeting drugs can cause side effects that include swelling and bleeding in the brain, and lecanemab did as well. One type of this swelling was seen in about 13% of recipients. Eisai said most were mild or asymptomatic.
Also, two deaths have been publicly reported among lecanemab users who also were taking blood-thinning medications for other health problems. Eisai said Tuesday the deaths can't be attributed to the Alzheimer's drug.
But Mayo's Petersen said if lecanemab is approved for use in the U.S., he'd avoid prescribing it to people on blood thinners at least initially.
And Thambisetty said the death reports raise concern about how the drug may be tolerated outside of research studies "where patients are likely to be sicker and have multiple other medical conditions."
The Food and Drug Administration is considering approving lecanemab under its fast-track program, with a decision expected in early January. If approved, it would be the second anti-amyloid drug on the market.
Nearly all treatments available for the 6 million Americans with Alzheimer's -- and millions more worldwide with the most common form of dementia -- only temporarily ease symptoms. Scientists don't yet know exactly how Alzheimer's forms but one theory is that gunky amyloid buildup plays a key role, although drug after drug that targets it has failed.
In a contentious move last year, the FDA approved the first amyloid-targeting drug, Biogen's Aduhelm, despite lack of evidence of better patient outcomes. Insurers and many doctors have hesitated to prescribe the pricey drug -- another reason experts have anxiously awaited word of how well the newer lecanemab may work.
If the FDA approves lecanemab, patients and their families will need a voice in deciding whether it's worth the hassle of IV infusions and the risk of side effects for the chance of at least some delay in progression, Petersen said.
"I don't think we're going to stop the disease in its tracks" with just amyloid-targeting drugs, he added, saying it will take a combination of medications that target additional Alzheimer's culprits.
Researchers are preparing to test lecanemab with other experimental drugs, and how it works in high-risk people before they show the first signs of memory problems.
------------
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
Air quality advisories are in effect across Western Canada as smoky conditions plague some areas, according to the latest forecasts. Here's where.
Many foods fall under the category of ultraprocessed foods, depending on their exact ingredients. This type of food has been studied a lot lately, and the results aren’t great.
Hollywood actor Steve Buscemi has been treated for injuries after being punched in the face while walking in New York City.
Four years on, the controversy over whether airlines owed refunds to passengers after cancelling hundreds of thousands of flights during the pandemic continues to simmer, aggravated by a sluggish, opaque complaints process.
For her latest column on CTVNews.ca, royal commentator Afua Hagan writes about Prince Harry and Meghan Markle's recent visit to Nigeria, calling it a 'deeply meaningful campaign' that was about aligning their ongoing efforts to foster mental-health awareness and promoting the Invictus Games.
As a pair of wildfires burn near Flin Flon and The Pas, a number of Manitobans are being told to evacuate their homes.
Ontario will need 33,200 more nurses and 50,853 more personal support workers by 2032, the government projects — figures it tried to keep secret but were obtained by The Canadian Press.
A tiny contingent of Duke University graduates opposed pro-Israel comedian Jerry Seinfeld speaking at their commencement in North Carolina Sunday, with about 30 of the 7,000 students leaving their seats and chanting "free Palestine" amid a mix of boos and cheers.
Whether you were lucky to nab tickets to one of Taylor Swift's six sold-out Toronto concerts in November or not, a new 'fan experience' hopes to get you into the party spirit.
Two daughters and a mother were reunited online 40 years later thanks to a DNA kit and a Zoom connection despite living on three separate continents and speaking different languages.
Mother's Day can be a difficult occasion for those who have lost or are estranged from their mom.
YES Theatre Young Company opened its acclaimed kids’ show, One Small Step, at Sudbury Theatre Centre on Saturday.
An Ottawa pizzeria is being recognized as one of the top 20 deep-dish pizzas in the world.
A family of fifth generation farmers from Ituna, Sask. are trying to find answers after discovering several strange objects lying on their land.
A Listowel, Ont. man, drafted by the Hamilton Tigercats last week, is also getting looks from the NFL, despite only playing 27 games of football in his life.
The threat of zebra mussels has prompted the federal government to temporarily ban watercraft from a Manitoba lake popular with tourists.
A small Ajax dessert shop that recently received a glowing review from celebrity food critic Keith Lee is being forced to move after a zoning complaint was made following the social media influencer’s visit last month.
The Canada Science and Technology Museum is inviting visitors to explore their poop. A new exhibition opens at the Ottawa museum on Friday called, 'Oh Crap! Rethinking human waste.'